StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR)

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research note published on Thursday morning. The firm issued a sell rating on the stock.

A number of other equities research analysts have also recently issued reports on NSPR. Piper Sandler reissued an “overweight” rating and set a $4.50 target price on shares of InspireMD in a report on Tuesday, September 17th. Lake Street Capital initiated coverage on InspireMD in a research note on Wednesday. They issued a “buy” rating and a $5.00 target price on the stock.

InspireMD Trading Down 4.5 %

InspireMD stock opened at $2.95 on Thursday. InspireMD has a 1-year low of $1.81 and a 1-year high of $3.42. The firm has a market capitalization of $76.95 million, a price-to-earnings ratio of -3.93 and a beta of 0.98. The firm’s fifty day moving average price is $2.66 and its two-hundred day moving average price is $2.68.

InspireMD (NYSE:NSPR) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The company had revenue of $1.81 million for the quarter, compared to analysts’ expectations of $1.74 million. During the same quarter in the previous year, the firm earned ($0.15) earnings per share. On average, research analysts forecast that InspireMD will post -0.79 EPS for the current year.

Institutional Trading of InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Parkman Healthcare Partners LLC acquired a new position in InspireMD, Inc. (NYSE:NSPR) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned 0.42% of InspireMD as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.